CombiGene – the gene therapy explorer

The goal for CombiGene is to develop treatment methods that can improve
the lives of milions of people all over the world.

Developing new treatment methods for neurological diseases, with higher precision, greater efficacy and fewer side effects.

CombiGene has, by combining advancements in neuroscience and modern gene therapy, developed a treatment method which is shown to prevent epileptic seizures. Currently, the company is focusing on further developing this treatment for the benefit of epilepsy patients, but this method has the potential to be developed for other neurological diseases. CombiGene’s office is located at Medicon Village in Lund and builds on research results from Lund University and the University of Copenhagen.

A STEP BY STEP TREATMENT

NORMAL BRAIN

Normal synaptic communication

NORMAL BRAIN

Normal glutamate release

EPILEPTIC BRAIN

Excessive glutamate release

EPILEPTIC BRAIN

Excessive synaptic communication

THE TREATMENT

Identification of Epileptic focus

THE TREATMENT

Preparing a gene vector Adeno associated virus

THE TREATMENT

DNA substitution

– NPY and Y2 transgenes in
– Viral DNA out

THE TREATMENT

Precision injection

– After identification of epileptic focus

THE TREATMENT

Vector enters brain cell

THE TREATMENT

Increased expression of NPY and Y2

THE TREATMENT

NPY and Y2 decreasing excessive glutamate release

THE TREATMENT

Back to normal synaptic communication

The focus for CombiGene is to produce a therapy for epileptic patients who cannot be helped by available medical treatments at present.

Read more »